Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 1/20 | 0.52 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.52 |
| ▸ | ACVR1 | Q04771 | 3/20 | 0.45 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.45 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.43 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.43 |
| ▸ | DHODH | Q02127 | 1/20 | 0.42 |
| ▸ | METAP2 | P50579 | 2/20 | 0.42 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.41 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.40 |
| ▸ | FEN1 | P39748 | 1/20 | 0.40 |
| ▸ | TDO2 | P48775 | 1/20 | 0.39 |
| ▸ | VHL | P40337 | 1/20 | 0.38 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15724372 | 0.84 | ACVR1 (0.43) | PRMT5WDR77ACVR1MAPK14PARP1 | |
| SCHEMBL2171957 | 0.76 | GLO1 (0.43) | ACVR1MAPK14PARP1 | |
| SCHEMBL15345124 | 0.75 | CCR1 (0.44) | MAPK14METAP2PARP1 | |
| SCHEMBL14484611 | 0.74 | ACVR1 (0.35) | PRMT5WDR77ACVR1MAPK14ALOX5AP | |
| SCHEMBL15730881 | 0.72 | ABL1 (0.46) | PRMT5WDR77ACVR1MKNK1MKNK2 | |
| SCHEMBL16805031 | 0.71 | ABL1 (0.52) | PRMT5WDR77MKNK1MKNK2DHODH | |
| SCHEMBL15730259 | 0.70 | FEN1 (0.57) | ACVR1MKNK2ALOX5APFEN1 | |
| SCHEMBL15730608 | 0.70 | ALDH1A1 (0.58) | PRMT5WDR77MAPK14MKNK1MKNK2 | |
| SCHEMBL15845828 | 0.70 | IP6K1 (0.56) | PRMT5WDR77ACVR1MKNK1MKNK2 | |
| SCHEMBL15341933 | 0.69 | MAPK14 (0.38) | ACVR1MAPK14PARP1ABL1TGFBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170137405-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. | 2017-05-18 | — | — | US | disclosed |
| US-20140142085-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. (US) | 2014-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170137405-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | CCR5, NPC1, FURIN | PRMT5 492/4885WDR77 417/4885ACVR1 3499/4885 |
| US-20140142085-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | CCR5, NPC1, FURIN | PRMT5 492/4885WDR77 417/4885ACVR1 3499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.